Environmental

Low Direct Environmental Footprint: As a clinical-stage biotechnology company, Abivax’s operations are primarily research-based, resulting in a relatively low direct environmental impact compared to manufacturing-based peers. There is no evidence of large-scale production or significant emissions at this stage.

Sustainability Reporting and Transparency: Abivax does not publish detailed sustainability or environmental impact reports, which is common among early-stage biotech firms but limits transparency for investors seeking ESG disclosures.

Product Lifecycle and Future Impact: With obefazimod in late-stage clinical trials, future commercialization could increase environmental risks related to manufacturing, supply chain, and waste management, though these are not yet material.

Abivax’s current environmental risks are moderate and typical for a clinical-stage biotech, with low direct impact but limited transparency. Future environmental risks may rise if products reach commercialization.

Social

Clinical Safety and Patient Impact: Obefazimod’s phase 3 results show a strong safety profile with minimal serious adverse events and no black-box warning expected, positioning Abivax favorably on patient safety versus peers.

Workforce Investment and R&D Focus: Abivax invests heavily in research and development, with R&D expenses representing over 26% of revenue, supporting talent retention and innovation.

Stakeholder Engagement and Institutional Support: Nearly 48% institutional ownership and increased holdings by asset managers reflect strong stakeholder confidence and engagement.

Abivax demonstrates strong social performance, driven by a robust clinical safety record, significant R&D investment, and high institutional engagement, supporting its reputation and stakeholder trust.

Governance

Board Oversight and Independence: Abivax’s board structure and governance practices are in line with industry norms, but there is limited public disclosure on board diversity and independence, which is a growing focus for investors.

Capital Discipline and Financial Oversight: The company maintains prudent capital discipline, as evidenced by a recent $748M capital raise and negative net debt, supporting operational runway and reducing financial risk.

Transparency and Regulatory Compliance: Abivax meets regulatory disclosure requirements and has not faced material compliance issues, but governance transparency could be improved, especially regarding ESG-specific policies.

Abivax’s governance is moderate, with sound financial oversight and regulatory compliance, but limited transparency on board composition and ESG-specific governance practices.

Overall Score

Abivax demonstrates strong overall ESG performance for a clinical-stage biotech, with leading social factors such as clinical safety and R&D investment, moderate governance, and low current environmental risk. The company’s ESG profile is supported by robust stakeholder engagement and prudent financial management, though transparency on environmental and governance disclosures could be improved.